Please login to the form below
Mitsubishi
This page shows the latest Mitsubishi news and features for those working in and with pharma, biotech and healthcare.
GSK files anaemia drug daprodustat in Japan, its first market
class called vadadustat in late-stage clinical testing that is licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan.
Latest news
-
Voice biomarker device could diagnose depression, heart disease
The financing round was led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, Germany), with MP Healthcare Venture Management (the corporate venture capital arm of Mitsubishi Tanabe
-
Biogen picks up another drug from wide-ranging Ionis alliance
It was joined last year by Mitsubishi Tanabe Pharma’s Radicava/Radicut (edaravone) last year, which provides another options, but there is still a desperate need for additional therapies.
-
Mitsubishi buys Israel's NeuroDerm for $1.1bn
Japan's Mitsubishi Tanabe Pharma has boosted its pipeline with a $1.1bn deal to buy NeuroDerm, an Israeli developer of central nervous system therapies. ... Adding ND0612 into the portfolio will help Mitsubishi meet its target of driving US sales to 80bn
-
FDA clears new ALS drug Radicava ahead of schedule
Patients with the chronic neurodegenerative disease amyotrophic lateral sclerosis (ALS) have a new treatment option in the US after the FDA approved Mitsubishi Tanabe Pharma's Radicava (edaravone).
-
GSK starts late-stage trials of daprodustat
Also in phase III is Akebia Pharma's vadadustat, which has been licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan.
More from news
Approximately 1 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD).
-
Deal Watch - May 2017
It is not known why in December 2015 the territorial rights granted to Mitsubishi for vadadustat for treatment of anaemia, were limited to Japan, SE Asia and India.
-
Japanese pharma pulls no punches with post-Brexit UK
The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and
-
Deal Watch November 2016
generic company and distributor. acquisition - company. 462. Kolon Life Science | TissueGene / Mitsubishi.
-
Deal Watch October 2016
$203m. Mitsubishi Tanabe (JP) / Sept 15. Biogen (US). amiselimod / multiple sclerosis.
More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
